Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Pfizer Inc. ( NYSE:PFE ) will increase its dividend from last year's comparable payment on the 7th of March to ...